<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487591</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-06009</org_study_id>
    <nct_id>NCT00487591</nct_id>
  </id_info>
  <brief_title>An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia</brief_title>
  <official_title>An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reliant Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Provident Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the effect of simvastatin plus Omacor to
      simvastatin plus placebo for lowering non-high density lipoprotein cholesterol in subjects
      with mixed dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 4
      (Week 0), after a 5-week diet lead-in/baseline period, subjects meeting all entry criteria
      will be randomized to one of two double-blind treatment sequences, simvastatin/Omacor first
      or simvastatin/placebo first. Each treatment period consists of 6 weeks. After randomization,
      subjects will self-administer the study drugs once a day in the evening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in non-high-density lipoprotein cholesterol (non-HDL-C)</measure>
    <time_frame>Baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in other lipid and biomarker levels</measure>
    <time_frame>Baseline through end of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Simva+Omacor</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Simva + Placebo</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omacor (omega-3-acid ethyl esters)plus simvastatin</intervention_name>
    <description>Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)</description>
    <arm_group_label>Simva+Omacor</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin plus placebo</intervention_name>
    <description>simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo</description>
    <arm_group_label>Simva + Placebo</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages 18-79 inclusive

          -  Fasting, untreated non-high-density lipoprotein cholesterol (non-HDL-C level above ATP
             III goals

          -  Fasting, untreated triglyceride (TG) level in the high to very high range

          -  Provide written informed consent and authorization for protected health information

        Exclusion Criteria:

          -  Pregnancy

          -  Use of lipid-altering drugs which cannot be stopped

          -  History of certain cardiovascular conditions or cardiac surgery within the prior 6
             months

          -  Body mass index above 40 kg per square meter

          -  Allergy or sensitivity to omega-3 fatty acids or to statin drugs

          -  Poorly-controlled conditions including diabetes, hypertension, or thyroid disease

          -  Certain muscle, liver, kidney, lung or gastrointestinal conditions

          -  Certain medications

          -  Active cancers treated within prior 2 years (except non-melanoma skin cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C Maki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Provident Clinical Research</affiliation>
  </overall_official>
  <results_reference>
    <citation>Maki KC; McKenney JM; Lubin BC; Reeves MS. Lipid effects of prescription omega-3-acid ethyl esters plus simvastatin in subjects with hypertriglyceridemia. FASEB J 2008;22:147.8</citation>
  </results_reference>
  <results_reference>
    <citation>Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008 Aug 15;102(4):429-33. doi: 10.1016/j.amjcard.2008.03.078. Epub 2008 May 22. Erratum in: Am J Cardiol. 2008 Nov 15;102(10):1425.</citation>
    <PMID>18678300</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <last_update_submitted>April 28, 2008</last_update_submitted>
  <last_update_submitted_qc>April 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kevin C. Maki, PhD, Chief Science Officer</name_title>
    <organization>Provident Clinical Research</organization>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>omega 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

